(Reuters) - The bipharmaceutical company said its independent data
monitoring committee recommended stopping the studies because
neither the main nor secondary goal was met.
The company was conducting two late-stage trials with
talabostat in combination with another cancer drug.
Read more at Reuters.com Government Filings News
monitoring committee recommended stopping the studies because
neither the main nor secondary goal was met.
The company was conducting two late-stage trials with
talabostat in combination with another cancer drug.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment